Our viewpoint on Neurosense Therapeutics (USA Stocks:NRSN) and Terns Pharmaceuticals (USA Stocks:TERN)?

In the world of biotechnology, risk and reward often walk hand in hand. This holds true for Neurosense Therapeutics (NRSN) and Terns Pharmaceuticals (TERN), two promising players in the industry. Despite the challenges, both companies have shown potential for growth and innovation. Neurosense, with a net asset of $3.18M and an enterprise value of $15.7M, has a high beta of 1.709, indicating a higher potential for returns, albeit with increased risk. On the other hand, Terns Pharmaceuticals, despite a net income loss of $11.3M, has a significant insider ownership of 28.56%, indicating a strong belief in the company's future. As we delve deeper into these companies, we will explore their potential and assess their investment outlook on the NASDAQ exchange. Many prudent traders are steering clear of the biotechnology sector. However, it's worth taking a closer look at Neurosense Therapeutics to understand its position relative to Terns Pharmaceuticals and similar companies. We will concentrate on some of the competitive elements of both Neurosense and Terns.
Published over three weeks ago
View all stories for Neurosense Therapeutics | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

Investing in Neurosense Therapeutics (NRSN) presents a compelling opportunity for investors seeking exposure in the biotechnology industry. Despite a net income loss from continuing operations of $11.3M, the company maintains a strong current ratio of 15.09X, indicating a robust liquidity position. The company's shares are also largely held by insiders, accounting for 28.56% of ownership, which could be a positive sign of management's confidence in the company's future. However, investors should be aware of the company's high selling and marketing expenses, which stand at $5.6M, and could impact the company's profitability in the short term.

Important Takeaways

Analyzing basic indicators between Neurosense Therapeutics and Terns allows for a comparison of how market volatilities affect both companies' prices. It also provides insight into whether they can diversify market risk if combined in a portfolio. Pair trading strategies can be utilized, matching a long position in Terns with a short position in Neurosense Therapeutics. For more information, refer to our pair correlation module. Examining Neurosense's assets reveals its asset utilization. It's important to note that Neurosense Therapeutics has a negative asset usage of -1.53%, losing $0.0153 for each dollar of assets the firm holds. This poor asset utilization suggests that the company is not effectively using each dollar of assets it secures. In essence, Neurosense Therapeutics' asset utilization indicates a lack of efficiency in its operations.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Neurosense Therapeutics. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its performance over time. Several factors influence the investment perspective on Neurosense Therapeutics, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.

Watch out for price decline

Please consider monitoring Neurosense Therapeutics on a daily basis if you are holding a position in it. Neurosense Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Neurosense Therapeutics stock to be traded above the $1 level to remain listed. If Neurosense Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Neurosense Therapeutics's Liquidity

Neurosense Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Neurosense Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neurosense Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Neurosense Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Neurosense Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Neurosense Therapeutics's total debt and its cash.

Neurosense Therapeutics Gross Profit

Neurosense Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Neurosense Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Neurosense Therapeutics Gross Profit growth over the last 10 years. Please check Neurosense Therapeutics' gross profit and other fundamental indicators for more details.

Another Deeper Perspective

Total Debt Breakdown

Now, let's check Neurosense Therapeutics total debt. Based on the latest financial disclosure, Neurosense Therapeutics has a Total Debt of 142 K. This is 99.99% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of Neurosense Therapeutics. As for Terns Pharmaceuticals we see total debt of 603 K, which is 99.81% lower than that of the Health Care
Sector
324.8 M
NRSN142,0000.0436
Sector324.78 Million99.77
TERN603,0000.19
"Never put all your eggs in one basket," is a timeless piece of financial wisdom that rings true when evaluating Neurosense Therapeutics (NRSN) and Terns Pharmaceuticals (TERN).
Neurosense, a player in the Biotechnology industry, has a high current ratio of 15.09X, indicating its strong ability to cover short-term liabilities. However, it reported a net income loss of $11.3M, which is concerning. Despite this, the company has a low total debt of $142K, which is a positive sign. Furthermore, Neurosense's market capitalization stands at $20.31M, with institutions owning 1.17% of the shares, suggesting some level of confidence from institutional investors. Overall, investors should consider the company's financial health and market position before making investment decisions..

Neurosense Therapeutics bad newscasts are not so bad

Despite negative news, Neurosense Therapeutics' situation may not be as bleak as it appears. The company's stock has seen a standard deviation decrease to 6.88, potentially indicating reduced volatility and suggesting a more stable investment than initially perceived. However, Neurosense Therapeutics, a potential penny stock, exhibits above-average volatility. While it may be a viable investment, many penny stocks are speculative and subject to artificial price hype. Investors are advised to understand the potential risks and rewards, and to be wary of signals such as unreported promotions, sudden news releases, or email spam. It's also recommended to research the backgrounds of company officers before investing in high volatility instruments or microcap equities.
While profits can be made from Neurosense if timed correctly, artificially hyped penny stocks often cannot sustain their increased share price for long. Shareholder value can only truly increase through solid performance backed by strong fundamentals.Despite the recent 6 percent decline in Neurosense Therapeutics' stock, the company still holds significant potential for investors. The Analyst Target Price Estimated Value is at $7.25, significantly higher than the current Valuation Real Value of $2.67. Furthermore, the Possible Upside Price is an impressive $8.06, indicating a potential for substantial returns. The Analyst Overall Consensus is a 'Strong Buy', backed by 1 Strong Buy and 1 Buy rating. However, investors should also be aware of the Possible Downside Price of $0.0116. Overall, despite the recent dip, Neurosense Therapeutics presents a compelling investment opportunity, especially for those willing to take on a bit of risk for potentially high returns..

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Neurosense Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com